Jefferies Financial Group Inc.
Position in ARWR — Arrowhead Pharmaceuticals, Inc.
CIK 96223
NEW YORK, NY
Position in ARWR
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$407,060
+$256,435 QoQ
Shares Held
4,994
-37.7% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#313
of 497 holders
Holding Since
Mar 2024
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARWR Over Time
Shares Held
Position Value (USD)
Derivatives in ARWR
reported options exposure · as of Dec 31, 2024CallValue
$0
CallShares
0
PutValue
$658,000
PutShares
35,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Jefferies Financial Group Inc. holds $677,219,224 across 66 Biotechnology names. ARWR ranks #52 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
1,357,042 | $110,693,915 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
2,199,652 | $80,947,193 | |
| 3 | IMTX |
Immatics N.V.
|
6,506,802 | $65,913,904 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
2,010,534 | $62,849,292 | |
| 5 | CGON |
CG Oncology, Inc.
|
769,947 | $54,704,734 | |
| 6 | ARGX |
Argenx SE
|
45,068 | $41,812,738 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
929,626 | $31,040,212 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
466,258 | $26,679,282 |
All Filings in ARWR
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $407,060 | 4,994 | Shares | Defined | 2026-08-17 | |
| 2024-12-31 | $150,625 | 8,012 | Shares | Defined | 2025-02-27 | |
| 2024-12-31 | $658,000 | 35,000 | Put | Defined | 2025-02-27 | |
| 2024-03-31 | $371,800 | 13,000 | Call | Defined | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||